Products
Platform
Research
Market
Learn
Compare PGIM India Healthcare Fund vs SBI Healthcare Opportunities Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹1000 | ₹500 |
Expense Ratio | 2.37 | 1.93 |
NAV | ₹9.89 | ₹433.33 |
Fund Started | 19 Nov 2024 | 04 Jun 1999 |
Fund Size | ₹104.81 Cr | ₹3933.26 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 90 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹1000
₹500
Expense Ratio
2.37
1.93
NAV
₹9.89
₹433.33
Fund Started
19 Nov 2024
04 Jun 1999
Fund Size
₹104.81 Cr
₹3933.26 Cr
Exit Load
Exit load of 0.50%, if redeemed within 90 days.
Exit load of 0.50% if redeemed within 15 days
Returns
1 Year | - | 3.27% |
3 Year | - | 25.40% |
5 Year | - | 18.81% |
1 Year
-
3.27%
3 Year
-
25.40%
5 Year
-
18.81%
Holding Analysis
Equity | 98.30% | 96.36% |
Cash | 0.08% | 3.56% |
Equity
98.30%
96.36%
Cash
0.08%
3.56%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.26% |
Divi's Laboratories Ltd. | 8.40% |
Max Healthcare Institute Ltd. | 7.40% |
Dr. Reddy's Laboratories Ltd. | 6.41% |
Aster DM Healthcare Ltd. | 6.09% |
Mankind Pharma Ltd. | 5.22% |
JB Chemicals & Pharmaceuticals Ltd. | 4.70% |
Krishna Institute of Medical Sciences Ltd | 3.91% |
Abbott India Ltd. | 3.32% |
Global Health Ltd. | 3.32% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.94% |
Divi's Laboratories Ltd. | 6.36% |
Max Healthcare Institute Ltd. | 5.67% |
Cipla Ltd. | 4.59% |
Lupin Ltd. | 4.08% |
Lonza Group Ag | 4.06% |
Fortis Healthcare Ltd. | 3.70% |
Torrent Pharmaceuticals Ltd. | 3.66% |
Gland Pharma Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.34% |
Fund Manager
Name | Vivek Sharma | Tanmaya Desai |
Start Date | 19 Nov 2024 | 17 May 2024 |
Name
Vivek Sharma
Tanmaya Desai
Start Date
19 Nov 2024
17 May 2024
About Fund
Description | The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 19 Nov 2024 | 04 Jun 1999 |
Description
The scheme seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
19 Nov 2024
04 Jun 1999